Literature DB >> 29177148

Descriptive Epidemiology of Hidradenitis Suppurativa in Greece: A Study of 152 Cases.

Alexandros C Katoulis1, Aikaterini I Liakou1, Nikolaos Rotsiamis1, Stefanos Bonovas2, Evangelia Bozi1, Efstathios Rallis3, Christos Christodoulou4, Dimitrios Rigopoulos1.   

Abstract

BACKGROUND/
OBJECTIVE: Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease that remarkably affects the patients' quality of life. A prospective study of 152 HS patients was conducted in order to depict the clinico-epidemiological characteristics of HS patients in Greece.
MATERIALS AND METHODS: From February 2015 to August 2016, 152 patients attended the Hidradenitis Suppurativa Outpatient Clinic of our department. The most important clinico-epidemiological data of the patients were registered. Descriptive statistics and an ordered logistic regression analysis were performed.
RESULTS: Of the 152 patients, 60.5% were females. Their median age was 37 years. A total of 26.3% of the patients suffered from Hurley stage I, 44.7% from Hurley stage II, and 29.0% from Hurley stage III. The median duration of disease was 9 years. The most common site of involvement was the groins. The mean Dermatology Life Quality Index (DLQI) was higher for Hurley stage III. In multivariable analysis, only the body mass index was found to independently predict the disease severity.
CONCLUSION: Among the factors examined, the body mass index appears to independently predict the disease severity. Quality of life evaluation revealed a stronger impact compared to the international experience. To our knowledge, this is the first descriptive epidemiological study among HS patients in Greece.

Entities:  

Keywords:  Epidemiology; Family history; Greece; Hidradenitis suppurativa; Hurley stage; Smoking

Year:  2017        PMID: 29177148      PMCID: PMC5697517          DOI: 10.1159/000475822

Source DB:  PubMed          Journal:  Skin Appendage Disord        ISSN: 2296-9160


  35 in total

Review 1.  Hidradenitis suppurativa resulting in systemic amyloid A amyloidosis: a case report and review of the literature.

Authors:  Sasha D Girouard; Rodney H Falk; Helmut G Rennke; Joseph F Merola
Journal:  Dermatol Online J       Date:  2012-01-15

2.  Hidradenitis suppurativa and associated factors: still unsolved problems.

Authors:  Lukasz Matusiak; Andrzej Bieniek; Jacek Cezary Szepietowski
Journal:  J Am Acad Dermatol       Date:  2009-08       Impact factor: 11.527

3.  Comorbidities of hidradenitis suppurativa (acne inversa).

Authors:  Sabine Fimmel; Christos C Zouboulis
Journal:  Dermatoendocrinol       Date:  2010-01

4.  Hidradenitis Suppurativa in prepubescent and pubescent children.

Authors:  Noah Scheinfeld
Journal:  Clin Dermatol       Date:  2014-12-08       Impact factor: 3.541

5.  South Italy: A Privileged Perspective to Understand the Relationship between Hidradenitis Suppurativa and Overweight/Obesity.

Authors:  Gabriella Fabbrocini; Valerio De Vita; Marianna Donnarumma; Giuseppe Russo; Giuseppe Monfrecola
Journal:  Skin Appendage Disord       Date:  2016-07-14

6.  Hidradenitis Suppurativa Management in the United States: An Analysis of the National Ambulatory Medical Care Survey and MarketScan Medicaid Databases.

Authors:  Scott A Davis; Hsien-Chang Lin; Rajesh Balkrishnan; Steven R Feldman
Journal:  Skin Appendage Disord       Date:  2015-06-20

7.  Depression in patients with hidradenitis suppurativa.

Authors:  A J Onderdijk; H H van der Zee; S Esmann; S Lophaven; D N Dufour; G B E Jemec; J Boer
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-02-20       Impact factor: 6.166

8.  Psychosocial impact of hidradenitis suppurativa: a qualitative study.

Authors:  Solveig Esmann; Gregor B E Jemec
Journal:  Acta Derm Venereol       Date:  2011-05       Impact factor: 4.437

9.  The symptomatology of hidradenitis suppurativa in women.

Authors:  G B Jemec
Journal:  Br J Dermatol       Date:  1988-09       Impact factor: 9.302

10.  Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity.

Authors:  Florence Canoui-Poitrine; Jean E Revuz; Pierre Wolkenstein; Cédric Viallette; Germaine Gabison; Florence Pouget; Florence Poli; Ousmane Faye; Sylvie Bastuji-Garin
Journal:  J Am Acad Dermatol       Date:  2009-04-29       Impact factor: 11.527

View more
  3 in total

Review 1.  An Update on Health-Related Quality of Life and Patient-Reported Outcomes in Hidradenitis Suppurativa.

Authors:  J Mac Mahon; S Kirthi; N Byrne; C O'Grady; A M Tobin
Journal:  Patient Relat Outcome Meas       Date:  2020-02-10

2.  The measurement performance of the EQ-5D-5L versus EQ-5D-3L in patients with hidradenitis suppurativa.

Authors:  Alex Bató; Valentin Brodszky; L Hunor Gergely; Krisztián Gáspár; Norbert Wikonkál; Ágnes Kinyó; Ákos Szabó; Zsuzsanna Beretzky; Andrea Szegedi; Éva Remenyik; Norbert Kiss; Miklós Sárdy; Fanni Rencz
Journal:  Qual Life Res       Date:  2021-02-03       Impact factor: 4.147

3.  Hidradenitis Suppurativa (HS) prevalence, demographics and management pathways in Australia: A population-based cross-sectional study.

Authors:  Miriam Calao; Jodie L Wilson; Lynda Spelman; Laurent Billot; Diana Rubel; Alan D Watts; Gregor B E Jemec
Journal:  PLoS One       Date:  2018-07-24       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.